Introduction
The cornerstone of safety evaluations of medicines, food additives, pesticides, cosmetics, consumer products and other chemicals is risk assessment: the process of evaluating the hazardous properties of substances and conditions of exposure to ascertain the likelihood that humans and/or the environment will be adversely affected, and to characterise the nature of the effects which may be experienced (Derelanko, 2002) . The conventional risk assessment paradigm consists of four major steps: hazard identification, exposure assessment, dose-response assessment, and risk characterisation.
At present, the hazard identification and dose-response steps in the risk assessment paradigm are heavily focused on the elucidation of gross toxic effects such as acute lethality, organ-related toxicity, birth defects and cancer, as well as the doses at which these effects occur. To this end, toxicity tests using rodents, rabbits, dogs and other animals are relied upon as human surrogates. A number of the test methods in mainstream use today were first developed between 60 and 80 years ago (Trevan, 1927; Draize et al., 1944) . Using the results of animal tests to predict human health effects involves a number of uncertainties, including whether animal data are relevant to humans, and whether high doses administered to animals are relevant to lower doses to which humans may be exposed. Consequently, a number of ''uncertainty factors" of up to 10-fold each may be applied during the risk characterisation step to account for (i) uncertainty in extrapolating animal data to humans, (ii) uncertainty in extrapolating from data obtained in a study with less-than-lifetime exposure to lifetime exposure, (iii) uncertainty associated with extrapolation from animal data when the database is incomplete, (iv) uncertainty in extrapolating from a ''LOAEL" rather than a NOAEL, and (v) variation in sensitivity among members of the human population, including between infants/children and adults. Thus, a compounded uncertainty factor of up to 10,000-fold is not unheard of (NRC, 2000) .
In recent years, the ''3Rs" principle of replacement, reduction and refinement (Russell and Burch, 1959) has gained a higher profile in toxicology due to a convergence of scientific, ethical/animal welfare, financial and legislative imperatives. For instance, many risk assessors would prefer to use mechanistically based empirical data in lieu of conservative extrapolation tools. Legislatively, a timetable for ending all cosmetics testing on animals has been established pursuant to the 7 th Amendment of the EUCosmetics Directive, while at the same time, the financial and animal welfare concomitants of applying the data requirements prescribed in the EU's Registration, Evaluation and Authorisation of Chemicals (REACH) regulation to between 30,000 and more than 140,000 chemicals will no doubt be profound (ECHA, 2009) . Furthermore, according to one set of national animal use statistics, up to 70% of the procedures that inflict the greatest animal suffering are undertaken for the purpose of regulatory toxicity testing (CCAC, 2008).
Scientific and practical limitations of current approaches
The current toxicological risk assessment paradigm has a number of limitations, which are largely rooted in the test methods used for hazard identification. Whereas formal validation to demonstrate relevance and reliability has become a prerequisite for regulatory acceptance of newly developed test methods, the great majority of toxicological studies in use today predate the existence of modern validation criteria (Hartung et al., 2004) and have never been scrutinised in such a systemic and rigorous manner (Balls, 2004) . However, the published literature is rife with case studies in which data from non-validated animal tests have been found to be poor predictors of real-world human effects (Basketter et al., 2004; NRC, 2006; Ekwall et al., 1998; Stanton and Spear, 1990; Ennever et al., 1987; Freeberg et al., 1986; Haseman, 1983; Salsburg, 1983; Weil and Scala, 1971) .
Some discoveries of interspecies differences come with grave consequences, as in the case with the clinical drug trial for TGN 1412, which nearly cost the lives of human study participants (Bhattacharya and Coghlan, 2006) . In the pharmaceutical sector, it is reported that 92% of drug candidates are abandoned during clinical trials for reasons including inefficacy and the discovery of toxic effects in humans that were not identified in preclinical animal testing (FDA, 2004) . The adequacy of conventional test methods has likewise been questioned in relation to sensitivity to endocrine-mediated adverse effects (EDSTAC, 1998), as well as for the hazard and risk assessment of nanoscale particles (SCENIHR, 2006) .
Additionally, the low-throughput and high cost of conventional toxicity testing methods and strategies limits their desirability and practical utility, both in general terms (Carmichael et al., 2006; McDougall, 2003) , and particularly as tools for responding to political and legislative mandates for the safety assessment of an increasingly large number of chemicals, mixtures and co-exposures. These factors have contributed to a daunting backlog of tens of thousands of chemicals and mixtures that have yet to be adequately assessed for their effects on human health and the environment -a situation that is compounded by the ongoing addition to the global marketplace of hundreds of new substances each year (GAO, 2005) .
In contrast, whereas available 3R methods generally offer certain advantages in terms of increased mechanistic relevance and/or reduced costs, testing time and animal use (Ayres et al., 2008; Hollinger and Derelanko, 2002) , they too have limitations. For example, most in vitro methods lack biotransformation capacity and cannot account for kinetic factors (i.e. absorption, distribution and elimination), which impedes reliable extrapolation of cellular/tissue-response data across several levels of biological organization to derive organism-level values such as NOAELs (ECHA, 2008) . Another consideration is the exorbitant time and cost involved in the development, validation and regulatory acceptance of 3Rs methods according to conventional procedures (EPAA, 2008).
Emerging technologies
The past two decades have seen unprecedented scientific and technological advances, including the birth of functional genomics, the explosive growth of computing power and computational biology/bioinformatics, the establishment of robotic platforms for high throughput chemical screening, and most recently, the sequencing of the human genome. Together, these advances have triggered a revolution in molecular biology, as well as the establishment of specialised research centres and collaborative initiatives across the EU and globally to explore and harness these new opportunities. One prominent example is the Netherlands Genomics Initiative, which operates a network of large-scale research centres and consortia that work on targeted programmes designed to generate societal and economic value from genomics (NGI, 2008) . Another example is the US National Institutes of Health Chemical Genomics Center (NCGC), which has developed an ultra-high throughput, in-house testing platform capable of profiling more than 1400 substances at 15 concentrations in 200 mechanistic assays in as little as two weeks (C. Austin, personal communication, 09.02.08). These and similar initiatives are generating vast amounts of data concerning the functioning of living organisms at the level of genes, proteins, metabolites and other cellular and biochemical components (MLI, 2008) . Given the promise of these new technologies, the International Life Sciences Institute (ILSI, 2008) has already convened an expert working group to explore issues germane to their regulatory acceptance and use in human health risk assessment.
Calls for a global paradigm shift
Some observers have assessed the scientific, ethical and practical limitations of conventional testing and risk assessment methods and called for nothing less than a fundamental paradigm shift in regulatory toxicology. As far back as 1980, Nobel laureate Dr. Joshua Lederberg wrote: ''It is simply not possible with all the animals in the world to go through new chemicals in the blind way that we have at the present time and reach credible conclusions about the hazards to human health. We are at an impasse...with deep scientific roots and we had better do something about it" (Lederberg, 1980) . Similar sentiments were recently expressed by a group of eminent scientists convened by the EPAA (2008), who concluded that: ''Truly innovative approaches to testing and risk assessment are needed for safe development of new products without recourse to animal experiments."
Discussion
A variety of proposals have been put forward in recent years to modernise aspects of toxicological testing and/or risk assessment (e.g. FDA, 2004; NTP, 2004; Carmichael et al., 2006; NRC, 2007; Collins et al., 2008; EPAA, 2008) ; however, one in particular stands out as providing a truly groundbreaking perspective. The 2007 report Toxicity Testing in the 21st Century: A Vision and a Strategy by the US National Research Council (NRC) envisions a not-so-distant future where virtually all routine toxicity testing will be conducted in human cells or cell lines in vitro by evaluating perturbations of cellular responses in a suite of toxicity pathway assays using rapid robotic-assisted methodologies (Andersen and Krewski, 2009 ).
The vision articulated by the NRC represents a fundamental departure from the conventional highdose/apical-effect paradigm in animals. Among its key attributes is an uncompromising focus on human, rather than rodent, biology, as well as the consideration of biological perturbations at exposure levels that are environmentally relevant.
The NRC vision is predicated on the aforementioned advances in molecular and computational biology. By integrating these tools and technologies, it becomes possible to mine large libraries of biological and chemical toxicity data, from which ''maps" of cellular pathways and responses can be generated. An initial effort along these lines has already begun under the auspices of the US Environmental Protection Agency (EPA) ToxCastTM initiative (EPA, 2008) , as well as through the ''Tox21" collaboration between the EPA, NCGC, and US National Toxicology Program (HHS and EPA, 2008; Collins et al., 2008) .
As toxicity pathways are identified, in vitro assays can be developed to study chemical interactions at key cellular and molecular targets within a pathway. Such assays may then be scaled up to high throughput platforms using robotic automation in order to test large numbers of compounds (Andersen and Krewski, 2009) . A parallel goal will be to broaden the suite of in vitro assays to encompass the as-yetundetermined number of critical toxicity pathways present in the human body. Computational systems biology models will also be needed to describe the ''circuitry" underlying each toxicity pathway as a basis for creating biologically based dose-response models. Subsequently, dose-dependent transition studies for sequential pathway activation can be undertaken to understand the linkage to cell-and tissue-level responses, i.e. the relationship between perturbations and adversity.
Ultimately, the NRC vision offers the promise of a more scientifically sound approach to risk assessment--and one with the capacity to examine a much larger number of chemicals, mixtures and biological outcomes at more relevant exposure levels than would be possible using conventional approaches; greater human relevance; reduced time, costs and animal use; and potentially, an end to animal testing altogether.
From roadmap to reality: bringing the vision to life
Implementation of the NRC vision of 21st century toxicology will require a large-scale, highly co-ordinated and well-funded interdisciplinary and international research effort on par with the Human Genome Project of the 1990s. The NRC itself has projected that the cost of implementing its vision could be on the order of hundreds of millions.
The Humane Society is heavily invested in seeing the NRC vision brought to fruition. One of us (MLS) was a member of the committee that produced the 2007 vision and roadmap report, and was part of the peer review panel for the new EPA (2009) toxicity testing strategic plan. Consistent with our long history of building partnerships for progress, we are assembling a multi-stakeholder consortium to promote dialogue and collaboration among corporate, academic and NGO leaders, and to act as a unifying vehicle for outreach to policymakers, regulators, business leaders and the public at large to encourage their support for and investment in the NRC vision. Already six multinational companies representing the chemical, consumer product and pharmaceutical sectors have joined this ''Human Toxicology Project Consortium," and discussions are ongoing with other corporate, academic and public interest organisations regarding potential membership in the consortium.
Additionally, the British office of Humane Society International -in partnership with the Flemish Institute for Technological Research (VITO) and the Freie Universität Berlin -is presently in negotiations with the European Commission to spearhead a multi-year, pan-European co-ordination project under the 7th EU Framework Programme for Research and Technology Development. The proposed ''AXLR8" project aims to establish a standing committee of leading scientists, host workshops and expert meetings to help shape future EU research activities in this area, and undertake pro-active outreach to the regulatory, scientific and other key stakeholder communities with the goal of accelerating the transition to a toxicity pathway-based paradigm for risk assessment.
Individuals and organisations interested in moving this process forward are invited to join with us in promoting the NRC vision and working towards its timely implementation. While ambitious in its scope, the success of the Human Genome Project has already proven that a similarly daunting task is achievable if there is sufficient will. The technology is for the most part already available; we now need to assemble the remaining tools for creating a new risk assessment paradigm that determines responses of human cells to chemical stressors and estimates the exposure conditions under which these responses are likely to have adverse consequences. And with a united, multi-stakeholder effort, it should be possible to revolutionise the field of toxicology over the course of the next decade or more for the benefit of science, public health, animal welfare and corporate interests alike.
